Esen Emel, Long Fanxin
Division of Biology and Biomedical Sciences, Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Curr Osteoporos Rep. 2014 Dec;12(4):433-8. doi: 10.1007/s11914-014-0235-y.
Osteoblasts, the chief bone-making cells in the body, are a focus of osteoporosis research. Although teriparatide, a synthetic fragment of the human parathyroid hormone (PTH), has been an effective bone anabolic drug, there remains a clinical need for additional therapeutics that safely stimulates osteoblast number and function. Work in the past several decades has provided unprecedented clarity about the roles of growth factors and transcription factors in regulating osteoblast differentiation and activity, but whether these factors may regulate cellular metabolism to influence cell fate and function has been largely unexplored. The past few years have witnessed a resurgence of interest in the cellular metabolism of osteoblasts, with the hope that elucidation of their metabolic profile may open new avenues for developing bone anabolic agents. Here we review the current understanding about glucose metabolism in osteoblasts.
成骨细胞是人体主要的造骨细胞,是骨质疏松症研究的重点。尽管特立帕肽,一种人甲状旁腺激素(PTH)的合成片段,已成为一种有效的骨合成代谢药物,但临床上仍需要其他能够安全刺激成骨细胞数量和功能的治疗方法。过去几十年的研究以前所未有的清晰度揭示了生长因子和转录因子在调节成骨细胞分化和活性中的作用,但这些因子是否通过调节细胞代谢来影响细胞命运和功能在很大程度上尚未得到探索。在过去几年中,人们对成骨细胞的细胞代谢重新产生了兴趣,希望阐明其代谢特征可能为开发骨合成代谢药物开辟新途径。在此,我们综述了目前对成骨细胞葡萄糖代谢的认识。